Electronic voting

Former STB Commissioner and Vice-Chairman, William Clyburn, Jr., Believes CN Voting Trust Should Be Approved

Retrieved on: 
Thursday, June 10, 2021

In the op-ed, Clyburn states he believes the CN voting trust addresses unlawful control and the public interest under the new rules, and that as such, the voting trust should be approved.

Key Points: 
  • In the op-ed, Clyburn states he believes the CN voting trust addresses unlawful control and the public interest under the new rules, and that as such, the voting trust should be approved.
  • The new rules were designed to require applicants to formally meet these tests before the Board would approve the use of a voting trust.
  • Prior to adoption of the Major Merger Rules, parties proposing use of a voting trust were free to use it without Board approval.
  • As part of the 2001 proceeding, we wanted more authority over and transparency into the voting trust process.

Former STB Commissioner and Vice-Chairman, William Clyburn, Jr., Believes CN Voting Trust Should be Approved

Retrieved on: 
Thursday, June 10, 2021

In the op-ed, Clyburn states he believes the CN voting trust addresses unlawful control and the public interest under the new rules, and that as such, the voting trust should be approved.

Key Points: 
  • In the op-ed, Clyburn states he believes the CN voting trust addresses unlawful control and the public interest under the new rules, and that as such, the voting trust should be approved.
  • The new rules were designed to require applicants to formally meet these tests before the Board would approve the use of a voting trust.
  • Prior to adoption of the Major Merger Rules, parties proposing use of a voting trust were free to use it without Board approval.
  • As part of the 2001 proceeding, we wanted more authority over and transparency into the voting trust process.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Retrieved on: 
Wednesday, June 9, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Retrieved on: 
Wednesday, June 9, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Tuesday, June 8, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc

Retrieved on: 
Tuesday, June 8, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Retrieved on: 
Tuesday, June 8, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.

Retrieved on: 
Tuesday, June 8, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Retrieved on: 
Tuesday, June 8, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Monday, June 7, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO